<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<oembed>
  <author_name>marfan-info</author_name>
  <author_url>https://blog.hatena.ne.jp/marfan-info/</author_url>
  <blog_title>海外マルファン情報 | Global Marfan Updates</blog_title>
  <blog_url>https://marfan-info.hatenablog.com/</blog_url>
  <categories>
    <anon>オンラインセミナー</anon>
    <anon>薬</anon>
    <anon>血管型エーラス・ダンロス症候群（vEDS）</anon>
  </categories>
  <description>Managing HTAD: Key Insights from the 2024 ESC Guidelines 28:35-29:22 Talking about medical treatment briefly, so Marfan syndrome, there's evidence in Marfan syndrome for beta blockers or an angiotensin receptor blocker (ARB), so losartan as the most known example here, should be given, recommended a…</description>
  <height>190</height>
  <html>&lt;iframe src=&quot;https://hatenablog-parts.com/embed?url=https%3A%2F%2Fmarfan-info.hatenablog.com%2Fentry%2F2025%2F02%2F25%2F224059&quot; title=&quot;2024 ECSガイドラインについて　〜薬物療法〜 - 海外マルファン情報 | Global Marfan Updates&quot; class=&quot;embed-card embed-blogcard&quot; scrolling=&quot;no&quot; frameborder=&quot;0&quot; style=&quot;display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;&quot;&gt;&lt;/iframe&gt;</html>
  <image_url></image_url>
  <provider_name>Hatena Blog</provider_name>
  <provider_url>https://hatena.blog</provider_url>
  <published>2025-02-25 22:40:59</published>
  <title>2024 ECSガイドラインについて　〜薬物療法〜</title>
  <type>rich</type>
  <url>https://marfan-info.hatenablog.com/entry/2025/02/25/224059</url>
  <version>1.0</version>
  <width>100%</width>
</oembed>
